Germany’s recently initiated Global Health Hub has the task to contribute to the Agenda 2030 sustainability goals by improving healthcare on a global scale. We want to focus on an aspect that Germany is admired for worldwide: technology. But since developing innovative therapies and diagnostics custom-made for the needs of developing world patients is not exactly a no-brainer, can German companies come up with a business model that is both fair and viable?